Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18324877 | 0.86 | TP53 (0.39) | ALDH1A1TP53MAPTPOLBNEK2 | |
| SCHEMBL18324872 | 0.86 | KCNH2 (0.48) | ALDH1A1TP53MAPTPOLBKCNH2 | |
| SCHEMBL18324880 | 0.84 | KDM4E (0.47) | ALDH1A1F12 | |
| SCHEMBL20016358 | 0.83 | TP53 (0.38) | ALDH1A1CYP2C19TP53MAPTPOLB | |
| SCHEMBL18324883 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPTTSHRMAPK1 | |
| SCHEMBL18324779 | 0.79 | TP53 (0.43) | ALDH1A1TP53 | |
| SCHEMBL2675756 | 0.71 | HTR1D (0.41) | POLBGAAKCNH2 | |
| SCHEMBL2676005 | 0.68 | ALDH1A1 (0.51) | ALDH1A1CYP2C19MAPTGAAMAPK1 | |
| SCHEMBL6645803 | 0.66 | NOS3 (0.44) | ALDH1A1CYP2C19TP53MAPTPOLB | |
| SCHEMBL15829995 | 0.66 | ALDH1A1 (0.61) | ALDH1A1CYP2C19MAPTPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | ALDH1A1 3981/4885CYP2C19 64/4885TP53 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.